



## PAYAL KOHLI, MD, FACC

450 UNIVERSITY BOULEVARD, CHERRY CREEK, DENVER, CO 80206  
PHONE 617-763-3827 • E-MAIL PAYAL.KOHLI@POST.HARVARD.EDU

### EDUCATION

---

**Harvard Medical School**

Doctor of Medicine

*M.D. degree awarded Magna Cum Laude (with honors)*

Boston, Massachusetts

Sept. 2002-June 2007

**Massachusetts Institute of Technology (M.I.T)**

Bachelor of Science in Biology

Bachelor of Science in Brain and Cognitive Sciences

Concentration in Economics

*Awarded Most Outstanding Academic Record (GPA 5.0/5.0)*

Cambridge, Massachusetts

Sept. 1998-June 2002

### POST-GRADUATE TRAINING

---

**University of California San Francisco (UCSF)**

**Clinical Fellowship in Cardiovascular Medicine**

San Francisco, California

*ABIM Board Certified in Cardiovascular Medicine 10/2015*

July 2012-June 2015

**University of California San Francisco (UCSF)**

**Clinical Fellowship in Cardiovascular Disease Prevention**

San Francisco, California

July 2014-June 2015

**University of California San Francisco (UCSF)**

**Clinical Fellowship in Advanced Echocardiography**

San Francisco, California

*ASE Board Certified in Comprehensive Echocardiography 7/2015*

July 2014-June 2015

**Thrombolysis in Myocardial Infarction (TIMI) Study Group  
Clinical Research Fellowship** July 2011-June 2012

Harvard Medical School, Dept. of Cardiovascular Medicine  
Clinical Trials in Cardiovascular Disease Diagnosis, Prognosis and Prevention  
Boston, Massachusetts

**Brigham & Women's Hospital/Harvard Medical School** July 2007-June 2008

**Internship and Residency, Internal Medicine** Aug. 2009-June 2011

Boston, Massachusetts

*ABIM Board Certified in Internal Medicine 8/2011*

**Harvard Business School** July-August 2010

Value-Based Health Care Delivery

Boston, Massachusetts

**Massachusetts General Hospital/Harvard Medical School** June 2008-July 2009

**Residency, Anesthesia & Critical Care**

Boston, Massachusetts

*Beecher Fellow (only 2 selected per residency class for faculty appointment at MGH)*

## WORK EXPERIENCE

---

**9News/9Health KUSA (NBC) On-Air Medical Expert** January 2020-present

**'Daily Blast Live' National On-Air Medical Expert** March 2020-present

**Heart and Vascular Institute of Colorado** November 2017-October 2019

Division of Cardiology

Noninvasive Cardiologist; Clinical Lead, Women's Heart Program;

Site Lead, Good Samaritan Hospital; Vice Chair of Cardiovascular Services;

Medical Director, Good Samaritan Hospital Cardiac Rehabilitation

Denver, CO

**Colorado Permanente Medical Group (Kaiser Permanente)**

Division of Cardiology

Noninvasive Cardiologist

Denver, CO

August 2015-September 2017

## CERTIFICATIONS AND LICENSURES

---

Board-certified in Internal Medicine, ABIM (August 2011-August 2021), number 313389

Board-certified in Cardiovascular Medicine (October 2015- October 2025), number 313389

Board-certified and Level 3 certified in Comprehensive Echocardiography, National Board of Echocardiography certification (July 2015-June 2025).

ARDMS Registered Physician in Vascular Interpretation (RPVI) certification (January 2015-December 2025), number 186862

Board-certified Level 2 certified in Nuclear Cardiology, Certification Board of Nuclear Cardiology (December 2016-March 2027), certificate number 11051

Board-eligible Level 2 certified in Cardiac CT.

Colorado Medical License (Active full license) #DR.0054941  
 DEA certification  
 Massachusetts Medical License (lapsed)  
 California Medical License (lapsed)

## SELECTED PUBLICATIONS

---

### **Original Investigations**

1. Fukunaga K, **Kohli P**, Bonnans C, Fredenburgh LE, Levy BD. Cyclooxygenase 2 Plays a Pivotal role in the Resolution of Acute Lung Injury. *J Immunol.* 2005. 174(8): 5033-9.
2. Levy BD, **Kohli P**, Gotlinger K, Haworth O, Hong S, Kazani S, Israel E, Haley KJ, Serhan CN. Protectin D1 is Generated in Asthma and Dampens Airway Inflammation and Hyper-responsiveness. *J Immunol.* 2007. 178(1): 496-502.
3. **Kohli P**, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, Murphy SA, Braunwald E, Lee RT, Morrow DA. Evaluation of ST2 in Non-ST Elevation Acute Coronary Syndromes in the MERLIN-TIMI 36 Trial. *Clin Chem.* Jan 2012.
4. **Kohli P**, Desai NR, Giugliano RP, Kim J, Somaratne R, Huang F, Knusel B, McDonald S, Abrahamsen T, Wasserman MD SM, Scott R, Sabatine MS. Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II Double-Blind Placebo Controlled Study of the Efficacy and Tolerability of A Monoclonal Antibody Inhibitor of PCSK9 in Subjects with Hypercholesterolemia on Background Statin Therapy. *Clin Card.* 2012;35(7):385-91. doi: 10.1002/clc.22014. Epub 2012 Jun 19.
5. Giugliano RP, Desai NR, **Kohli P**, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS. A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of a Monoclonal Antibody to PCSK9 in Combination with a Statin in Patients with Hypercholesterolemia. *Lancet*, 2012. doi: 10.1016/S0140-6736(12)61770-X.
6. **Kohli P**, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP. Reduction in First and Recurrent Cardiovascular Events with Ticagrelor Compared with Clopidogrel in the Plato Study. *Circulation.* 2013;127(6):673-80.
7. Desai NR, **Kohli P**, Giugliano RP, O'Donoghue M, Somaratne R, Zhou J, Hoffman E, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS. AMG 145, A Monoclonal Antibody Against PCSK9, Significantly Reduces Lipoprotein (a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LAPLACE-TIMI 57 Trial. *Circulation.* 2013 Jul 24. DOI: 10.1161/CIRCULATIONAHA.113.001969.
8. Makadia SS, Blaha MJ, Keenan T, Ndumele C, Jones S, DeFilippis, A, Martin SS, **Kohli P**, Conceicao RD, Carvalho JA, Nasir K, Blumenthal RS, Santos R. Hepatic Steatosis Associated with Dyslipidemia Independent of Obesity, Metabolic Syndrome, Inflammation, & Physical Activity. *Am J Cardiol.* 2013 Sep 5. pii: S0002-9149(13)01621-4. doi: 10.1016/j.amjcard.2013.08.001.
9. **Kohli P**, Udell JA, Murphy SA, Cannon CP, Antman EM, Braunwald E, Wiviott SD. Discharge Aspirin Dose and Clinical Outcomes in Patients with Acute Coronary Syndromes treated with Prasugrel vs. Clopidogrel: An Analysis from the TRITON-TIMI 38 study. *J Am Coll Cardiol.* 2013 Oct 1. pii: S0735-1097(13)05456-9. doi: 10.1016/j.jacc.2013.09.023.
10. Desai NR, Giugliano RP, Zhou J, **Kohli P** et al. AMG 145, A Monoclonal Antibody Against PCSK9, Facilitates Achievement of NCEP-ATP III LDL-C Goals Among High Risk Patients: An Analysis From the LAPLACE-TIMI 57 Trial. *J Am Coll Cardiol.* 2013 Oct 11. pii: S0735-1097(13)05608-8. doi: 10.1016/j.jacc.2013.09.048.
11. **Kohli P**, Steg G, Cannon CP, Smith SC, Eagle KA, Ohman EM, Alberts MJ, Hoffman E, Guo J, Simon T, Sorbets E, Goto S, Bhatt DL. NSAID use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease: 4-Year Results from the REACH Registry. *Am J*

- Med.* 2014 Jan;127(1):53-60.e1. doi: 10.1016/j.amjmed.2013.08.017. Epub 2013 Nov 23.
12. Udell JA, Wang TY, Li S, **Kohli P**, Roe MT, Lemos JA, Wiviott SD. Clinical Trial Participation after Myocardial Infarction in a National Cardiovascular Data Registry. *JAMA.* 2014;312(8):841-843. doi:10.1001/jama.2014.6217.
  13. **Kohli P**, Waters DD, Nemr R, et al. Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non-Pre-Diabetics: An Analysis From TNT and IDEAL. *J Am Coll Cardiol.* 2015;65(4):402-404. doi:10.1016/j.jacc.2014.10.053.
  14. Pinto D. S., **Kohli P.**, Fan W., Kirtane A. J., Kociol R. D., Meduri C., Deliargyris E. N., Prats J., Reynolds M. R., Stone G. W. and Michael Gibson C. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database. *Cathet. Cardiovasc. Intervent.* 2015. doi: 10.1002/ccd.26023.
  15. **Kohli P**, Ganz P, Ma Y, Scherzer R, Hur S, Weigel B, Grunfeld C, Deeks S, Wasserman S, Scott R, Hsue PY. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox". *J Am Heart Assoc.* 2016 Apr 29;5(5). pii: e002683. doi: 10.1161/JAHA.115.002683.
  16. Arsenault BJ, **Kohli P**, Lambert G, DeMicco DA, Laskey R, Messig MM, Kastelein JP, Waters DD. Emerging cardiovascular disease biomarkers and incident diabetes risk in statin-treated patients with coronary artery disease. *Am J Card.* 2016 Aug 15;118(4):494-8. doi: 10.1016/j.amjcard.2016.05.044. Epub 2016 May 29.
  17. **Kohli P**, Knowles JW, Sarraju A, Waters DD, Reaven G. Metabolic Markers that Predict Incident Diabetes in Statin-Treated Patients: Analysis from TNT and SPARCL. *Am J Card*, 2016 Nov 1;118(9):1275-1281. doi: 10.1016/j.amjcard.2016.07.054. Epub 2016 Aug 12.
  18. Abassi F, **Kohli P**, Reaven GM, Knowles JW. Hypertriglyceridemia: A simple approach to identify insulin resistance and enhanced cardio-metabolic risk in patients with prediabetes. *Diabetes Res Clin Pract.* 2016 Aug 6;120:156-161. doi: 10.1016/j.diabres.2016.07.024.

### Editorials

1. **Kohli P**, Cannon CP. Statins and Safety: Can We Finally Be Reassured? *Lancet.* 2011. 6736(11): 61544-4.
2. **Kohli P** and Cannon CP. An Approach to Managing the ‘Statin-Intolerant’ Patient?” *Eur Heart J*, 2012. 33:1040-43.
3. **Kohli P** and Cannon CP. Dabigatran Associated with Increased Risk of Coronary Events. *Evid Based Med.* 2013 Feb;18(1):e9. doi: 10.1136/eb-2012-100733. Epub 2012 Jun 27.
4. Cannon CP and **Kohli P**. Danger Ahead: Watch Out for Indirect Comparisons. *J Am Coll Cardiol.* 2012;60 (8):747-748. doi:10.1016/j.jacc.2012.
5. **Kohli P** and Cannon CP. The Importance of Matching Language to Type of Evidence: Avoiding the Pitfalls of Reporting Outcomes Data. *Clin Card.* 2012 doi: 10.1002/clc.22066.
6. **Kohli P**, Chandrashekhhar Y, Narula J. Restructured Format for Condensed Abstracts: Vini, Vidi, Vici. *J Am Coll Cardiol. Img.* 2013;6(11):1220-1221.
7. Czarny MJ, Martin SS, **Kohli P**, Metkus T, Blumenthal RS. Nonfatal Outcomes in the Primary Prevention of Atherosclerotic Cardiovascular Disease: Is All-Cause Mortality Really All That Matters? *Circ Cardiovasc Qual Outcomes.* 2014;7:00-00. DOI: 10.1161/CIRCOUTCOMES.114.000871.
8. **Kohli P** and Waters DD. Looking for coronary disease in patients with atrial fibrillation. *Can J Cardiol.* 2014 Aug;30(8):861-3. doi: 10.1016/j.cjca.2014.06.001. Epub 2014 Jun 11.
9. Shaw LJ, **Kohli P**, Chandrashekhhar Y, Narula J. Cardiovascular Imaging of Women: We Have Come a Long Way But Still Have a Ways to Go. *JACC Cardiovasc Imaging.* 2016 Apr;9(4):502-3. doi: 10.1016/j.jcmg.2016.02.012.
10. **Kohli P**, Agarwala A, Virani SS. Popular Media and Cardiovascular Medicine: “With Great Power There Must Also Come Great Responsibility” *Curr Atheroscler Rep.* 2019 Oct 31;21(11):43. doi: 10.1007/s11883-019-0807-5.
11. **Kohli P** and Virani SS. Surfing the Waves of the COVID-19 pandemic. *Circulation, accepted, publication*

*pending.*

### **Reviews, chapters, and monographs**

1. **Kohli P** and Levy BD. Resolvins and Protectins: The fatty solution to resolving inflammation. *Br J Pharm.* 2009.
2. **Kohli P**. "Anesthesia for Urological Surgery" chapter in Ehrenfeld, J., Urman, R., Segal S. "Anesthesiology: A Case Based Guide For Students" Springer 2010.
3. **Kohli P** and Morrow DA. "Evolving Biomarkers for Cardiac Ischemia" chapter in Januzzi, J. "Cardiac Biomarkers in Clinical Practice: Present and Future Applications" Jones and Bartlett 2011.
4. **Kohli P** and Cannon CP. "Triglycerides: How Much Credit Do They Deserve?" *Medical Clinics of North America.* Coronary Risk Factors Update, January 2012.
5. **Kohli P** and Cannon CP. Acute Coronary Syndromes in 2011. *Nature Reviews Cardiology*, 2011.
6. Chakrabarti AK, Patel SJ, **Kohli P**, Udell JA, Singh P, Gopalakrishnan L, Kumar V, Gibson, CM. Cost-effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation. *J Atrial Fibrillation*, 2012.
7. Gopalakrishnan L, Kumar V, **Kohli P**, Singh P, Rastogi U, Gibson CM. Pharmacokinetic Evaluation of Rivaroxaban for the Treatment of Thrombosis. *Exp Opin on Drug Metabolism and Toxicology*, 2012 Jul;8(7):889-900. Epub 2012 May 11.
8. **Kohli P**, Giugliano RP. Low-Density Lipoprotein Lowering in 2013 by Nonstatin Agents: The Discovery and Development of Promising Novel Targeted Therapies. *J Cardiovasc Pharmacol Ther* 2013;18(3):199-210.
9. Chrispin J, Martin SS, Hasan RK, Joshi PH, Minder CM, McEvoy JW, **Kohli P**, Johnson AE, Wang L, Blaha MJ, Blumenthal RS. Landmark Lipid-Lowering Trials in the Primary Prevention of Cardiovascular Disease. *Clin Cardiol* 2013;10.1002/clc.22147.
10. Hsu S, Ton VK, Dominique Ashen M, Martin SS, Gluckman TJ, **Kohli P**, Sisson SD, Blumenthal RS, Blaha MJ. A Clinician's Guide to the Abcs of Cardiovascular Disease Prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. *Clin Cardiol* 2013;10.1002/clc.22137.
11. **Kohli P** and Schiller N. "Right Ventricular Physiology" chapter in American Society of Echocardiography *Dynamic Echocardiography* 2014.
12. **Kohli P**, Whelton SP, Hsu S, Yancy CW, Stone NJ, Chrispin J, Gilotra NA, Houston B, Ashen MD, Martin SS, Joshi PH, McEvoy JW, Gluckman TJ, Michos ED, Blaha MJ, Blumenthal RS. A Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. *J Am Heart Assoc.* 2014 Sep 22;3(5). pii: e001098. doi: 10.1161/JAHA.114.001098.
13. Jia X, **Kohli P**, Virani SS. Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials. *Curr Atheroscler Rep.* 2019 Jan 10;21(1):1. doi: 10.1007/s11883-019-0763-0.
14. Flink L, **Kohli P**, Schiller N. "The Physiologic Basis of Right Ventricular Echocardiography" chapter in American Society of Echocardiography *Dynamic Echocardiography* 2019.

### **Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings**

1. **Kohli P**, Carter EP, McMurtry IF. Inhibition of K<sub>Ca</sub> channels restores blunted hypoxic pulmonary vasoconstriction in rats with cirrhosis. *American Thoracic Society International Conference*, Denver, May 2001.
2. **Kohli P**, Levy BD, Serhan CN. A Novel Docosatriene (10,17S-DT) is a Potent Inhibitor of Airway Inflammation and Hyper-responsiveness. *Society for Leukocyte Biology Conference*, Philadelphia, October 2003.
3. **Kohli P**, Levy BD, Serhan CN. A Novel Docosatriene (10,17S-DT) is a Potent Inhibitor of Airway Inflammation and Hyper-responsiveness. *Harvard Medical School Health Sciences and Technology Forum*, Boston, March 2004.
4. **Kohli P**, Morrow D, Jarolim P, Sloan S, Sabatine M. Myeloperoxidase (MPO) is an Independent Predictor of Adverse Cardiovascular Outcomes in Patients with Stable Coronary Artery Disease.

- Circulation*. 2010;122:A13175.
5. **Kohli P**, Jadhav AP, Cho, TA. Occult Breast Cancer Manifests as Paraneoplastic Limbic Encephalitis and Stiff Person Syndrome. *American College of Physicians*, San Diego, April 2011.
  6. Udell J, **Kohli P**, Li S, Wang TY, Antman EM, Wiviott SD. Clinical Trial Participation After Acute Coronary Syndrome and Associated Outcomes: Insight from the Action Registry – GWTG. *J Am Coll Cardiol*. 2012;59(13s1):E1806-E1806. doi:10.1016/S0735-1097(12)61807-5.
  7. **Kohli P**, Morrow DA, Murphy SA, Cannon CP, Ridker PM, Braunwald E, Sabatine MS. Prognostic Value of Serial C-Reactive Protein Levels after an Acute Coronary Syndrome: An Analysis from PROVE-IT TIMI 22. *J Am Coll Cardiol*. 2012;59(13s1):E399-E399. doi:10.1016/S0735-1097(12)60400-8.
  8. **Kohli P**, Wallentin L, Reyes E, Horrow J, Husted S, Storey R, James SK, Cannon CP. Reduction in First and Recurrent Cardiovascular and Ischemic Events With Ticagrelor Compared With Clopidogrel in the PLATO Study. *J Am Coll Cardiol*. 2012;59(13s1):E504-E504. doi:10.1016/S0735-1097(12)60505-1.
  9. **Kohli P**, Udell JA, Murphy SA, Antman EA, Braunwald E, Wiviott SD. Discharge Aspirin Dose and Clinical Outcomes in Patients with ACS: An Analysis from the TRITON-TIMI 38 study. *J Am Coll Cardiol*. 2012;59(13s1):E342-E342. doi:10.1016/S0735-1097(12)60343-X.
  10. **Kohli P**, Murphy SA, Cannon CP. Who Funds The Evidence in the ESC Guidelines: Government or Industry? Analysis of Class I Acute Coronary Syndrome Recommendations from 2011. *Circ Cardiovasc Qual Outcomes*. 2012;5:A204.
  11. **Kohli P**, Chakrabarti A, Bansilal S, Dangas G, Nienaber C, Prats J, Gibson CM. Reduction in Mortality from Thrombin Inhibition in CHF patients: Results from the PREMIER Hospital Database. *European Society of Cardiology*, Munich, Germany, 2012.
  12. **Kohli P**, Murphy SA, Cannon CP. Who Funds the Evidence in the ESC Guidelines: Government or Industry? Analysis of the Class I Acute Coronary Syndrome Recommendations from 2011. *European Society of Cardiology*, Munich, Germany, 2012.
  13. **Kohli P**, Steg PG, Crowley K, Murphy SA, Goto S, Bhatt DL. NSAID Use is Associated with An Increase in Adverse Cardiac Events: 4-year results from the REACH Registry. *European Society of Cardiology*, Munich, Germany, 2012. Awarded “Best Scientific Content and Highest Scoring Abstract” at ESC 2012.
  14. **Kohli P**, Laine L, Kaur A, Curtis S, Cannon CP. Atrial Fibrillation/Flutter Associated with Rheumatoid Arthritis vs. Osteoarthritis and the use of Etoricoxib vs. Diclofenac: Results from the MEDAL Program. *Circulation (suppl.)* 2012;126: A19248.
  15. **Kohli P**, Desai NR, Giugliano RP, Mohanavelu S, Hoffman EB, Liu T, Scott R, Wasserman SM, Sabatine MSS. Reduction in Lipoprotein (a) with the PCSK9 Inhibitor AMG145 in Hypercholesterolemic Patients on Background Statin: Results from the LAPLACE-TIMI 57 Trial. *Circulation (suppl.)* 2012; 126: A17630.
  16. Desai NR, **Kohli P**, Giugliano RP, O’Donoghue M, Somaratne R, Hoffman EB, Huang F, Wasserman SM, Scott R, Sabatine MS. AMG 145, A Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin type 9 (PCSK9), Facilitates Achievement of NCEP LDL-Cholesterol Goals in High-Risk Patients. *American Heart Association Scientific Sessions*, Los Angeles, CA, 2012.
  17. Makadia SS, Blaha MJ, Keenan T, Ndumele C, Jones S, DeFilippis, A, Martin SS, **Kohli P**, Conceicao RD, Carvalho JA, Nasir K, Blumenthal RS, Santos R. Hepatic Steatosis Associated with Dyslipidemia Independent of Obesity, Metabolic Syndrome, Inflammation, & Physical Activity. *J Am Coll Cardiol*. 2013;61(10\_S):E1430. doi: 10.1016/S0735-1097(13)61430-8.
  18. **Kohli P** and Ganz P. Stuck Between A Rock and A Hard Place: A Patient with Hypertrophic Cardiomyopathy and Cardiogenic Shock. *J Am Coll Cardiol*. 2014;63(12\_S):. doi:10.1016/S0735-1097(14)60665-3.
  19. **Kohli P**, Cohen B, Mishra R, Regan MC, Schiller NB. Illicit Drug And Diastolic Function: Data from the Mind Your Heart Study. *J Am Coll Cardiol*. 2014;63(12\_S):. doi:10.1016/S0735-1097(14)61081-0.
  20. **Kohli P**, Waters DD, Arsenault BJ, Messig M, Laskey R, Kastelein J. New-Onset Diabetes and Cardiovascular Risk Reduction from Statin Therapy Differ in Pre-Diabetics and Non-Pre-Diabetics: A

- TNT and IDEAL Substudy. *J Am Coll Cardiol*. 2014;63(12\_S):. doi:10.1016/S0735-1097(14)61284-5.
21. **Kohli P**, Messig MA, Laskey R, Arsenault B, Waters DD. Fasting blood glucose predicts cardiovascular risk in TNT and IDEAL. *European Society of Cardiology Scientific Sessions*, Barcelona, Spain, 2014.
  22. **Kohli P**, Ganz P, Ma Y, Scherzer R, Deeks SG, Maka K, Wasserman S, Scott R, Hsue P. PCSK9 Inhibition is an Attractive Target for Treating Dyslipidemia in HIV+ Patients. *American Heart Association Scientific Sessions*, Chicago, IL, 2014.
  23. **Kohli P**, Ganz P, Ma Y, Scherzer R, Deeks SG, Maka K, Grunfeld C, Wasserman S, Scott R, Hsue P. PCSK9 Inhibition is an Attractive Target for Treating Dyslipidemia in HIV+ Patients. *Conference on Retroviruses and Opportunistic Infections*, Seattle, WA, 2015.
  24. **Kohli P**, Waters DD, Fayyad R, Laskey R, DeMicco D, Knowles JW, Reaven G. Incidence of New-Onset Diabetes on Statin Therapy Increases with Increasing Baseline Triglycerides: Data from TNT. *American College of Cardiology Scientific Sessions*, San Diego, CA, 2015.
  25. **Kohli P**, Ganz P, Ma Y, Scherzer R, Deeks SG, Maka K, Grunfeld C, Wasserman S, Scott R, Hsue P. PCSK9 is Elevated in Patients with HIV and Hepatitis C. *American College of Cardiology Scientific Sessions*, San Diego, CA, 2015.
  26. Arsenault BJ, **Kohli P**, Lambert G, DeMicco DA, Laskey R, Messig MM, Kastelein JJ, Waters D. Emerging cardiovascular disease biomarkers and incident diabetes risk in statin-treated patients with coronary artery disease. *International Atherosclerosis Society*, Amsterdam, Netherlands, 2015.
  27. **Kohli P**, Knowles JW, Amarenco P, Fayyad R, Reaven GM, DeMicco DA, Arsenault B, Laskey R, Waters DD. TG/HDL Ratio Predicts Incident Diabetes and Cardiovascular Events in Prediabetics and Non-Prediabetics in TNT and SPARCL. *European Society of Cardiology Scientific Sessions*, London, United Kingdom, 2015.
  28. **Kohli P**, Wang A, Wang P, Liu L, Weinstein A, Spertus J, Piccini J, Curtis J, Makary M, Gluckman T. Predictors of FFR Underutilization. *American College of Cardiology World Congress*, Chicago, IL, 2020.

## EDITORIAL ACTIVITIES

---

### **Editorial Board Membership:**

**Current Atherosclerosis Reports**, Section Editor, Women and Ischemic Heart Disease (2019-present)  
**American College of Cardiology ACC.org**, Prevention Section Associate Editorial Team Lead (2017-present)  
**American College of Cardiology ACCEL**, Assistant Editor (2017-present)  
**Journal of the American College of Cardiology Cardiovascular Imaging**, Assistant Editor (2013-2017)  
**Journal of the American College of Cardiology**, Section Editor, Media (2014-2015)  
**Consultant Live Continuing Medical Education**, Editorial Board (2013-present)  
**CardioSource World News/Cardiology**, Editorial Consultant and Columnist (2012-2014), (2017-present)  
**Clinical Cardiology**, Editorial Board (2012-present)  
**Medscape Consult Chief Editor**, Cardiology (2018-present)

---

### **Ad Hoc Peer Reviewer:**

**American Journal of Cardiology**, Ad Hoc Reviewer (2011-present)  
**Journal of Thrombosis and Thrombolysis**, Ad Hoc Reviewer (2013-2015)  
**Annals of Internal Medicine**, Ad Hoc Reviewer (2011-12)  
**Critical Pathways in Cardiology**, Ad Hoc Reviewer (2011-2015)  
**Clinical Cardiology**, Ad Hoc Reviewer (2011-present)  
**Journal of Cardiovascular Pharmacology and Therapeutics**, Ad Hoc Reviewer (2011-present)  
**Reviews in Cardiovascular Medicine**, Ad Hoc Reviewer (2011-2015)  
**Public Library of Science**, Ad Hoc Reviewer (2011-2015)  
**Canadian Journal of Cardiology**, Ad Hoc Reviewer (2015-present), Awarded Recognized Reviewer (2015)  
**European Heart Journal**, Ad Hoc Reviewer (2018-present)  
**Journal of the American College of Cardiology Cardiovascular Imaging**, Reviewer (2018-present)  
**Current Atherosclerosis Reports** (2019-present)

**European Journal of Preventive Cardiology**, Ad Hoc Reviewer (2020-present)  
**American Journal of Cardiovascular Drugs** (2019-present)

## IN THE PRESS

---

In addition to those listed below, there are >270 On-Air appearances locally and nationally as well as radio and print journalism citations between 1/2020 and 4/2020. Available upon request.

1. **Kohli P.** Mile High Living, July 9, 2018. [http://x-default-stg.ec.uplynk.com/ausw/slices/3e5/0e3a3b3bc3ae4d6eac785fb8a26bdb6b/3e5dfd0e20ed4de9a94dd0adf61f2cfe/3e5dfd0e20ed4de9a94dd0adf61f2cfe\\_g.mp4](http://x-default-stg.ec.uplynk.com/ausw/slices/3e5/0e3a3b3bc3ae4d6eac785fb8a26bdb6b/3e5dfd0e20ed4de9a94dd0adf61f2cfe/3e5dfd0e20ed4de9a94dd0adf61f2cfe_g.mp4)
2. **Kohli P.** Doctors Respond: ORBITA Study Finds Stents Don't Ease Angina. November 7, 2017. <https://opmed.doximity.com/doctors-respond-orbita-study-finds-stents-dont-ease-angina-ed3c5dcd0edb>.
3. Saklecha A. Doximity OpEd. This Female Physician Is Tackling Gender Norms in Cardiology: **Dr. Payal Kohli**. August 2, 2017. <https://opmed.doximity.com/q-a-this-female-physician-is-tackling-gender-norms-in-cardiology-ada71485944a>.
4. **Kohli P.** CardioSmart: What Motivates You To Stay Heart Healthy? June 9, 2017.
5. <https://www.youtube.com/watch?v=dUy9BKYCSSg>.
6. McGuire R. CardioSource World News: NSAIDs Linked With Increased Risk in Stable CAD; Results from REACH Registry with **Dr. Payal Kohli**. <https://www.youtube.com/watch?v=PyRzbyEbxUc>. October 9, 2012.
7. **Kohli P.** CardioSource World News: The Great Debate on Statins in Primary Prevention with Dr. Rita Redberg. May 1, 2012.
8. **Kohli P.** ACC Scientific Sessions 2018 Featured Early Career Tweeter. Orlando, FL.
9. **Kohli P.** ACC Scientific Sessions 2019 Featured Early Career Tweeter. New Orleans, LA.

## AWARDS

---

Cornell University Presidential Scholarship (1998)  
 Wellesley College Book Award (1998)  
 Massachusetts Institute of Technology (MIT) Most Outstanding MedLink (1999)  
 Golden Key National Honor Society National Dean's List (2000, 2001)  
 Induction into National Society of Collegiate Scholars (2001)  
 Massachusetts Institute of Technology (MIT) Most Outstanding Associate Advisor (2001)  
 Massachusetts Institute of Technology (MIT) Most Outstanding Academic Record (2002)  
 Massachusetts Institute of Technology (MIT) Walle Nauta Research Award (2002)  
 Harvard Medical School Neil Ghiso Fellowship (2006)  
 Harvard Medical School *Magna Cum Laude* (2007)  
 Massachusetts General Hospital Beecher Research Scholarship (2008)  
 European Society of Cardiology Congress Best Scientific Content and Highest Scored Abstract (2012)  
 Best Fellow-in-Training Poster at American College of Cardiology Scientific Sessions (2013)  
 American Heart Association Women In Cardiology Trainee Award for Excellence (2013)  
 National Institutes of Health T32 Training Grant (2013)  
 Lamond Endowed Fellow in Cardiovascular Disease, University of California San Francisco (2014-15)  
 American College of Cardiology Bristol-Myers Squibb Award (2014)  
 American Heart Association Samuel A. Levine Young Clinical Investigator Award (2014)  
 National Institutes of Health (NIH) Loan Repayment Award (2014)  
 American College of Cardiology Young Investigator Award (2015)  
 Canadian Journal of Cardiology Recognized Reviewer (2015)  
 Conference on Retroviruses and Opportunistic Infections (CROI) Young Investigator Award (2015)  
 Doximity Fellowship (2015)



Fellow of the American College of Cardiology (2016-present)  
Doximity Authors (2018-2019)  
RockStar of The Rockies (2018)  
American College of Cardiology Leadership Academy (2020-2022)  
Doximity “Doxie” Award for Excellence (2020)

## PROFESSIONAL MEMBERSHIPS

---

American College of Cardiology  
American College of Cardiology, Women in Cardiology Council  
American College of Cardiology, Innovation Council  
American Heart Association  
American Society of Nuclear Cardiology  
American Society for Preventive Cardiology  
National Lipid Association

## PROFESSIONAL INTERESTS

---

Cardiovascular disease prevention, women’s cardiology, sports cardiology

## PERSONAL INTERESTS

---

Enjoying the outdoors, traveling, photography

## REFERENCES

---

**Peter Ganz, MD.** Chief of Cardiology and Director of the Center of Excellence in Vascular Research at the San Francisco General Hospital and Maurice Eliaser Distinguished Professor of Medicine at the University of California, San Francisco. [Peter.Ganz@ucsf.edu](mailto:Peter.Ganz@ucsf.edu)

**Anne Thorson, MD, MS.** Associate clinical professor of Medicine, Division of Cardiology at UCSF and associate director of the UCSF Center for Prevention of Heart and Vascular Disease. [Anne.Thorson@ucsf.edu](mailto:Anne.Thorson@ucsf.edu)

**Deepak Bhatt, MD, MPH.** Executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital (BWH) and professor of medicine at Harvard Medical School. [DBhatt@partners.org](mailto:DBhatt@partners.org).

Invited Presentations, Committee Service, Teaching Activities and Additional Publications are listed in the supplementary CV.

# PAYAL KOHLI, MD, FACC

## SUPPLEMENTARY CURRICULUM VITAE

### INVITED PRESENTATIONS

---

#### Local

<b>Harvard Medical School Combined MD/PhD Grand Rounds</b> “A 42-year old man with headache”	2006
<b>Brigham &amp; Women’s Hospital Heart Happenings Program: A Symposium for Patients Who Have Survived Heart Attacks</b> Department of Cardiovascular Medicine Brigham & Women’s Hospital Boston, MA	2011
<b>South Shore Hospital Cardiology Grand Rounds</b> “Approach to The Patient with low HDL” Weymouth, MA	2012
<b>University of California San Francisco Cardiovascular Division Grand Rounds</b> “The Role of PCSK9 in Cholesterol Homeostasis, Response to Statins and Cardiovascular Risk in HIV+ Patients” San Francisco, CA	2014
<b>American Heart Association PULSE Charity Fundraising Event</b> “The ABCs of Cardiovascular Prevention” (lay audience) San Francisco, CA	2015
<b>University of California San Francisco Primary Care Division Grand Rounds</b> “Heart Health in Women: 2015 Update” San Francisco, CA	2015
<b>University of California San Francisco Echocardiography Grand Rounds</b> “Echo for Transcatheter Aortic Valve Replacement” San Francisco, CA	2015
<b>University of California San Francisco Osher Mini Medical School for Lay Audience</b> “Cholesterol: What Is It and When To Treat It” San Francisco, CA	2015
<b>Kaiser Permanente Hospitalist Journal Club</b>	2015
<b>Kaiser Permanente Hospitalist Journal Club</b>	2016
<b>Optimal Duration of Anti-Platelet Therapy: Kaiser Permanente Primary Care Rounds</b> Highlands Ranch, CO	2017
<b>Ambulatory ECG Monitoring: Kaiser Permanente Primary Care Rounds</b> Parker, CO	2017

<b>Kaiser Permanente Hospitalist Journal Club</b>	2017
<b>Good Samaritan Hospital Grand Rounds</b> “Women’s Heart Health: Bridging the Gender Gap” Lafayette, Colorado	2018
<b>Good Samaritan Hospital Grand Rounds</b> “Hot Topics in Cardiology in 2019” Lafayette, Colorado	2019
<b>Regional</b> <b>REVEAL-TIMI 55 Investigator/Research Coordinator Meeting</b> “Atherosclerosis and LDL-lowering therapies” Boston, MA	2012
<b>REVEAL-TIMI 55 Investigator/Research Coordinator Meeting</b> “Atherosclerosis and LDL-lowering therapies” Miami, FL	2012
<b>Thrombolysis in Myocardial Infarction Scientific Symposium</b> “The Prognostic Utility of Serial C-Reactive Protein Levels after an Acute Coronary Syndrome: An Analysis from PROVE-IT TIMI 22” Chicago, IL	2012
<b>PLATO Steering Committee</b> “Reduction in First and Recurrent Cardiovascular and Ischemic Events with Ticagrelor Compared with Clopidogrel in the PLATO Study” Chicago, IL	2012
<b>Editors of the Heart Group Journals Board Meeting</b> (Editors-in-Chief of all premier cardiovascular journals) “The Importance of Matching Language to Study Type” Chicago, IL Munich, Germany	2012
<b>“Watchman: A Viable Option for Stroke Risk Reduction in Nonvalvular Atrial Fibrillation”</b> Denver, CO	2017
<b>ACC Colorado Chapter CHF Summit 2018</b> “Pain and Pleasure: The Clinical Case of A New Mother” Quiz the Cardiologists Colorado Springs, CO	2018
<b>ACC Colorado Chapter CHF Summit 2019</b> “Guideline Updates from 2019” “All You Need to Know About Maintaining Board Certification” Colorado Springs, CO	2019

**National/International**

<b>LAPLACE-TIMI 57: A Randomized Control Trial of AMG 145 (PCSK9 inhibitor) in Hypercholesterolemic Subjects on a Background of Statin Therapy</b>	2012
Full-day training session for national and international principal investigators to train on the background, rationale and protocol design of LAPLACE-TIMI 57. TIMI Study Group, Boston, MA (sponsored by Amgen, Inc.) Palmer House Hilton, Chicago, IL (sponsored by Amgen, Inc.) Radisson Blu, Amsterdam, Netherlands (sponsored by Amgen, Inc.)	
<b>Pfizer Atorvastatin Trials Advisory Board Statins and Risk of New-Onset Diabetes</b>	2014
New York, NY	
<b>Amgen HIV Evolocumab Advisory Board The Role of PCSK9 in Cholesterol Homeostasis in HIV+ Patients</b>	2014
Washington, DC	
<b>Co-Chair, American College of Cardiology Women in Cardiology Session “Crossing the Borders: Lessons from International Luminaries and Women Outside the Clinic” ACC Scientific Sessions 2016</b>	2016
Chicago, IL	
<b>Boston Scientific Watchman Noninvasive Faculty Advisory Board</b>	2018
Minneapolis, MN	
<b>ACC Scientific Sessions 2019 “Does My Patient Have Intermediate Risk or Indeterminate Risk?”</b>	2019
New Orleans, LA	
<b>Best of ACC 2019: China</b>	2019
Faculty Shanghai, Guangzhou, Foshan, China	
<b>Boston Scientific Faculty Leadership Program</b>	2019
Minneapolis, MN	
<b>Watchman Education Program “An Imager’s Perspective on Watchman Patient Selection”</b>	2019
Denver, CO	
<b>Esperion Lipid Lowering Advisory Board</b>	2019
Salt Lake City, UT	
<b>Watchman Education Program “AF Stroke Risk Reduction Strategies: Economic Considerations for the Payer, the Provider and the Patient”</b>	2019
New York, NY	

Amgen

**COMMITTEE SERVICE**

---

**National and Regional**

Massachusetts Medical Society CME Committee	2008-2009
ACC CardioSource Usability Workgroup	2012-2014
ACC Women in Cardiology Leadership Council	2013-2015
ACC Fellows in Training, Career Development Leader	2015-2016
MIT Educational Council	2017-present
Practicing Wisely Board of Advisors	2018-present
Doximity Authors	2018-present
Grand Rounds Expert Consultation	2018-2019
ACC/ACCSAP/ABIM Performance Question Writer	2019-present
Doximity Advisory Board	2019-present
Trustee to Board of Advisors, Colorado ACC	2019-present

**Local**

Harvard Medical School M.D. Admissions Committee	2005-2007
BWH Code Team and Emergency Response Committee	2009-2011
BWH Housestaff Committee	2009-2011
BWH Intensive Care Unit Curriculum Redesign Task Force	2010-2011
BWH Clinical Pathological Correlation/NEJM Case (CPC) Committee	2010-2011
BWH Drug Safety Committee	2010-2011
BWH Housestaff Selection Committee	2010-2011
Harvard Medical School of M.D. Advisors	2010-2012
Kaiser Permanente Lipid Guidelines Committee	2016-2017
Heart & Vascular Institute of Colorado/Good Samaritan Hospital Site Lead	2017-present
SCL Health Women's Heart Health Steering Committee, Chair	2018-present
Good Samaritan Hospital Cardiovascular Services, Vice Chair	2019-present
Good Samaritan Hospital Performance Excellence Committee	2019-present

**TEACHING ACTIVITIES**

---

**Mentoring of Trainees**

<b>Anubha Agarwal, B.S.</b> , Stanford University, candidate for M.D., Stanford University
<b>Farnaz Azarbal, M.D.</b> , Cardiology Fellow, University of California San Francisco
<b>Sameer Bhutani, candidate for B.S.</b> , University of San Francisco
<b>Kara Yeung, B.S.</b> , Stanford University, <b>candidate for M.D.</b> , Harvard University
<b>Colleen Campbell, NP</b> , candidate for Masters of Nursing, Kaiser Permanente Colorado

**Teaching of Students in Courses**

<b>Harvard Medical School Molecular Biology and Genetics in Modern Medicine</b>	August-Dec. 2003
Teaching Assistant for 1 <sup>st</sup> year medical and 2 <sup>nd</sup> and 3 <sup>rd</sup> year PhD students	
<b>Harvard Medical School Musculoskeletal Pathophysiology</b>	January 2005
Teaching Assistant for 1 <sup>st</sup> year medical and 2 <sup>nd</sup> and 3 <sup>rd</sup> year PhD students	
<b>Harvard Medical School Human Reproductive Biology</b>	August-Nov. 2005

Teaching Assistant for 2<sup>nd</sup> year medical and 2<sup>nd</sup> and 3<sup>rd</sup> year PhD students

**Harvard Medical School Introduction to Clinical Medicine**

February-May 2010

Clinical Preceptor for 2<sup>nd</sup> year medical students

**Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)**

**Airway Management for the Internist**

2009

1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> year medicine residents

**Teaching Resident**

2010

1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> year medicine residents

**Intravenous Conscious Sedation Certification Course**

2010-2011

2<sup>nd</sup> and 3<sup>rd</sup> year medicine residents

**Fundamental and Contemporary Topics in Cardiology**

2012-13

1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> year medicine residents, 3<sup>rd</sup> and 4<sup>th</sup> year medical student, and pharmacy students

**Heart Health in Women: What You May be Missing**

2015

Primary care faculty, 1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> year medicine residents, 3<sup>rd</sup> and 4<sup>th</sup> year medical student, and pharmacy students

**Clinical Supervisory and Training Responsibilities**

**General Medical Service**

2009

Brigham & Women's Hospital

Supervising Resident for Sub-Interns

**General Medical Service**

2010

Brigham & Women's Hospital

Preceptoring 3<sup>rd</sup> year medical students, who are taking histories and performing physical examinations.

**Cardiology Consultation Service**

2013

University of California, San Francisco

Preceptoring 4<sup>th</sup> year medical students, and 2<sup>nd</sup> year medical residents rotating on the cardiology consultation service.

**Laboratory and Other Research Supervisory and Training Responsibilities**

Training of undergraduate students and research technicians

2004-2006

Brigham & Women's Hospital

Boston, Massachusetts

**ADDITIONAL PUBLICATIONS**

---

**Case Reports**

1. **Kohli P.** Mr. M: A case study of pulmonary pathology. Online publication from BIDMC Radiology department. <http://eradiology.bidmc.harvard.edu/LearningLab/respiratory/Kohli.pdf> eradiology.bidmc.harvard.edu/LearningLab/respiratory/Kohli.pdf, 2004.
2. **Kohli P,** Agarwal A, Goldschlager N. ECG Quiz. *J Electrocard.* 2014 Jan-Feb. 47 (1):120–122.

**Thesis**

**Kohli P.** The Pivotal Role of Lipid Mediators in Resolution of Inflammation: Frontiers for New Therapeutic Targets.

**Textbook Contributions**

1. **Kohli P.** Medical student contributor to review text accompanying Abbas, Lichtman and Pober, *Cellular and Molecular Immunology*. 2005.
2. **Kohli P.** "Anesthesia for Urological Surgery" chapter in Ehrenfeld, J., Urman, R., Segal S. "Anesthesiology: A Case Based Guide For Students" Springer 2010.
3. **Kohli P** and Cannon CP. "Triglycerides: How Much Credit Do They Deserve?" *Medical Clinics of North America*. Coronary Risk Factors Update, January 2012.

**Patient-Targeted Publications and Presentations**

1. **Kohli P.** Chest Pain: When to Worry? <http://health.yahoo.net/experts/heartsmartliving/when-chest-pain-really-heart-pain>. Accessed April 23, 2013.
2. **Kohli P.** The ABCs of Cardiovascular Prevention. Your Healthy Heart Newsletter – UCSF Heart and Vascular Center Prevention Newsletter. March 2015.
3. **Kohli P.** Living a Healthy Life. Good Health Magazine. Summer 2018.
4. **Kohli P.** Let's Have A Heart-To-Heart and Talk Heart Health. SCL Health Blogs. <https://www.sclhealth.org/blog/2019/03/lets-have-a-heart-to-heart-and-talk-heart-health/>. Accessed March 19, 2019.
5. **Kohli P.** "Common Myths about Women's Heart Disease and Steps Towards Prevention" February 28, 2019

**Online Peer-Reviewed Publications**

1. **Kohli P.** Guideline Education: Non-Pharmacologic Management of Hypertension. January 16, 2017. [http://edu.acc.org/diweb/catalog/item/id/2060564?\\_ga=2.60740525.1412441718.1542558834-1373292999.1522853237](http://edu.acc.org/diweb/catalog/item/id/2060564?_ga=2.60740525.1412441718.1542558834-1373292999.1522853237). Accessed January 23, 2018.
2. Velagapudi P and **Kohli P.** Imaging for Ischemia in Women with Suspected Coronary Artery Disease. [http://edu.acc.org/diweb/catalog/item/id/2450956?\\_ga=2.60740525.1412441718.1542558834-1373292999.1522853237](http://edu.acc.org/diweb/catalog/item/id/2450956?_ga=2.60740525.1412441718.1542558834-1373292999.1522853237). Accessed November 18, 2018.
3. Jia X, Miedema MD, Virani SS, **Kohli P.** Expert Analysis: Not All Fish Oils Created Equal: Insight From REDUCE-IT. <https://www.acc.org/latest-in-cardiology/articles/2018/11/14/13/59/not-all-fish-oils-are-created-equal>. November 14, 2018.
4. Mehta LS, Saeed A, **Kohli P.** Cholesterol Management in Women: What Does the 2018 Guideline Tell Us? <https://www.acc.org/latest-in-cardiology/articles/2019/04/11/09/04/cholesterol-management-in-women>. April 11, 2019.
5. Smith N, Virani SS, **Kohli P.** Blumenthal RS, Martin SS. Key Takeaways Comparing Lipid Guidelines Across the Pond: The Hot Off the Press 2019 ESC vs. 2018 ACC/AHA Guidelines. <https://www.acc.org/latest-in-cardiology/articles/2019/09/09/13/08/key-takeaways-comparing-lipid-guidelines-across-the-pond>. September 9, 2019.

**Online Non-Peer Reviewed Publications and Essays**

1. **Kohli P.** "The Tax Man Cometh" Fellows in Training Column, Cardiosource World News. March 2012.
2. **Kohli P.** "Mobile Technology and Learning on the Go" Fellows in Training Column, Cardiosource World News. April 2012.
3. **Kohli P.** "California or Bust" Fellows in Training Column, Cardiosource World News. May 2012.
4. **Kohli P.** "Degrees Degrees Everywhere" Fellows in Training Column, Cardiosource World News. June 2012.
5. **Kohli P.** "Disagreeing with Attendings" Fellows in Training Column, Cardiosource World News. July 2012.
6. **Kohli P.** "Stupid Consults" Fellows in Training Column, Cardiosource World News. August 2012.

7. **Kohli P.** “What’s Your Number?” Fellows in Training Column, Cardiosource World News. September 2012.
8. **Kohli P.** “The Thrill of Academic Medicine” Fellows in Training Column, Cardiosource World News. October 2012.
9. **Kohli P.** “What Would You Be If Not a Doctor?” Fellows in Training Column, Cardiosource World News. November 2012.
10. **Kohli P.** “Practicing What We Preach: On Being a Good Doctor and a Good Patient?” Fellows in Training Column, Cardiosource World News. December 2012.
11. **Kohli P.** “Is Facebook the New Textbook?” Fellows in Training Column, Cardiosource World News. January 2013.
12. **Kohli P.** “Greetings from ACC.13’s Host City!” Fellows in Training Column, Cardiosource World News. February 2013.
13. **Kohli P.** “Are We Doctors or Politicians?” Fellows in Training Column, Cardiosource World News. March 2013.
14. **Kohli P.** “The Role of The Physician In the Internet Age.” Fellows in Training Column, Cardiosource World News. April 2013.
15. **Kohli P.** “Breaking Into The Boys Club?” Fellows in Training Column, Cardiosource World News. May 2013.
16. **Kohli P.** Has Medicine Become *TOO* Standardized? May 2013. <http://www.cardioexchange.org/voices/has-medicine-become-too-standardized/>
17. **Kohli P.** Women in Cardiology. May 2013. <http://blog.cardiosource.org/post/Women-in-Cardiology.aspx>
18. **Kohli P.** “The Challenge of Global Cardiology?” Fellows in Training Column, Cardiosource World News. June 2013.
19. **Kohli P.** “The Medical Caste System?” Fellows in Training Column, Cardiosource World News. July 2013.
20. **Kohli P.** “A Plane Crashed at SFO” July 10, 2013. <http://www.cardioexchange.org/voices/a-plane-just-crashed-at-sfo/>
21. **Kohli P.** “Brain Drain from Medicine.” Fellows in Training Column, Cardiosource World News. August 2013.
22. **Kohli P.** Women in Cardiology. August 2013. <http://blog.cardiosource.org/post/Women-in-Cardiology.aspx>.
23. **Kohli P** and Hira R. Leaving Behind the Baggage. <http://www.acc.org/membership/sections-and-councils/fellows-in-training-section/fit-information-hub/career-development/2015/09/22/09/31/leaving-behind-the-baggage>. September 22, 2015.
24. **Kohli P.** Conversations with Kohli: Patient Generated Data: A Physician’s Friend or Foe? <https://www.acc.org/latest-in-cardiology/articles/2018/02/13/14/42/conversations-with-kohli-patient-generated-health-data-a-physicians-friend-or-foe>. February 16, 2018.
25. **Kohli P.** Conversations with Kohli: Patient Generated Data: Are Physicians the Weakest Link in Bringing A New Drug to Market? <http://www.acc.org/latest-in-cardiology/articles/2018/03/28/14/42/conversations-with-kohli-are-physicians-the-weakest-link-in-bringing-a-new-drug-to-market>. March 30, 2018.
26. **Kohli P.** Conversations with Kohli: Patient Generated Data: Bursting Your Bubble! <http://www.acc.org/latest-in-cardiology/articles/2018/04/17/12/42/conversations-with-kohli-bursting-your-bubble> . April 25, 2018.
27. **Kohli P.** Conversations with Kohli: Are Doctors Smarter than A Hamster? <https://www.acc.org/latest-in-cardiology/articles/2018/05/14/24/42/conversations-with-kohli-are-we-smarter-than-a-hamster>. May 16, 2018.
28. **Kohli P.** Conversations with Kohli: Patient Generated Data: Bursting Your Bubble! Medical Education in 2018: Is this Progress? <https://www.acc.org/latest-in-cardiology/articles/2018/06/11/08/42/conversations-with-kohli-medical-education-in-2018-is-this-progress>. June 14, 2018.
29. **Kohli P.** Conversations with Kohli: The Strange Case of Dr. Jekyll and Mr. Hyde. <https://www.acc.org/latest-in-cardiology/articles/2018/07/06/12/42/conversations-with-kohli-the-strange-case-of-dr-jekyll-and-mr-hyde>. July 23, 2018.
30. **Kohli P.** Doximity Op-Med: “Patient Generated Data: Physician’s Friend or Foe?” [https://opmed.doximity.com/patient-generated-health-data-a-physicians-friend-or-foe-93080aa96591https://www.doximity.com/doc\\_news/v2/entries/13298585](https://opmed.doximity.com/patient-generated-health-data-a-physicians-friend-or-foe-93080aa96591https://www.doximity.com/doc_news/v2/entries/13298585). July 24 2018.
31. **Kohli P.** Doximity Op-Med: “Are Physicians The Weakest Link in Bringing A New Drug to Market” [https://opmed.doximity.com/are-physicians-the-weakest-link-in-bringing-a-drug-into-practice-5e02a8b49687https://www.doximity.com/doc\\_news/v2/entries/13986344](https://opmed.doximity.com/are-physicians-the-weakest-link-in-bringing-a-drug-into-practice-5e02a8b49687https://www.doximity.com/doc_news/v2/entries/13986344). September 11, 2018.
32. **Kohli P.** Conversations with Kohli: Are We Ever Really Out of Office? <https://www.acc.org/latest-in-cardiology/articles/2018/09/14/24/42/conversations-with-kohli-are-we-ever-really-out-of-office>. September 20,



- 2018.
33. **Kohli P.** Doximity Op-Med: “Is Medical Education Progressing or Regressing” [https://opmed.doximity.com/is-medical-education-progressing-or-regressing-2158972b817ehttps://www.doximity.com/doc\\_news/v2/entries/14434899](https://opmed.doximity.com/is-medical-education-progressing-or-regressing-2158972b817ehttps://www.doximity.com/doc_news/v2/entries/14434899). October 10, 2018.
  34. **Kohli P.** Doximity Op-Med: “Not to Burst Your Bubble”. [https://www.doximity.com/doc\\_news/v2/entries/14826527](https://www.doximity.com/doc_news/v2/entries/14826527). November 5, 2018.
  35. **Kohli P.** Conversations with Kohli: Getting Off The Screen. <https://www.acc.org/latest-in-cardiology/articles/2018/10/14/12/42/conversation-with-kohli-getting-off-the-screen>. October 19, 2018.
  36. **Kohli P.** Doximity Op-Med: Is A Doctor Ever Really ‘Out of Office?’
  37. **Kohli P.** Matters of the Heart: Engaging The Next Generation of Cardiologists. <https://www.acc.org/latest-in-cardiology/articles/2018/11/06/12/42/conversations-with-kohli-matters-of-the-heart-engaging-the-next-generation-of-cardiologists>. November 16, 2018.
  38. <https://opmed.doximity.com/articles/is-a-doctor-ever-really-out-of-office>. December 17, 2018.
  39. **Kohli P.** Doximity Op-Med: Forget ‘Get Off The Couch’ – What About Screens? <https://opmed.doximity.com/articles/forget-get-off-the-couch-what-about-screens>. January 14, 2019.
  40. **Kohli P.** Conversations with Kohli: What’s Your “Muse”? <https://www.acc.org/latest-in-cardiology/articles/2019/01/07/12/42/conversations-with-kohli-whats-your-muse>. January 18, 2019.
  41. **Kohli P.** Conversations with Kohli: When The System Fails Us. <https://www.acc.org/latest-in-cardiology/articles/2019/05/07/12/42/conversations-with-kohli-when-the-system-fails-us>. May 17, 2019.
  42. **Kohli P.** Best of ACC in China: My Experience, My Perspectives. <https://www.acc.org/latest-in-cardiology/articles/2019/07/11/12/42/feature-best-of-acc-in-china-my-experience-my-perspectives>. Feature, *Cardiology*, July 19, 2019.

#### **Proceedings of meetings or other non-peer reviewed research publications**

1. **Kohli P.** “New Horizons in Atrial Fibrillation.” *Selected Reports from the American Heart Association Scientific Sessions*. Orlando, Florida, November 2011. <http://www.cardiologyreport.com>.
2. **Kohli P.** “American Heart Association Scientific Sessions 2011 Wrap-up”, November 2011, Orlando, FL. [http://tv.clinicaltrialresults.org/play.php?submission\\_id=1066](http://tv.clinicaltrialresults.org/play.php?submission_id=1066).
3. **Kohli P** and Cannon CP. “Statins and Safety: Essentials for the Primary Care Physician.” <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2024090>
4. **Kohli P** and Cannon CP. “The Basics About Women and Cardiovascular Disease: What Does The Primary Care Physician Need to Know?” <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2042583>.
5. **Kohli P** and Cannon CP. “Preview of ACC.12 and ACC-i2 with TCT.” <http://www.cardiosource.org/News-Media/CardioSource-Video-News.aspx?vidid=yTzK83Rtv0uhYdSiS41mxA>.
6. **Kohli P.** The Great Debate: Rita Redberg, MD. May 1, 2012. American College of Cardiology Scientific Sessions 2012. <http://www.youtube.com/watch?v=ymDCWPQ0vWw&noredirect=1>
7. **Kohli P** and Cannon CP. “Managing the Statin Intolerant Patient: Tips for the Primary Care Physician.” <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2104924>.
8. **Kohli P** and Antman EA. “Highlights from the American Heart Association Scientific Sessions 2012: Take-Home Messages for the Primary Care Physician” November 2012. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2115295>.
9. **Kohli P.** Vascular Shark Tank. *Cardiology*. Coverage from ACC Scientific Sessions 2019.
10. **Kohli P.** Future Hub Keynote: Realizing the Potential of Technology. *Cardiology*. Coverage from ACC Scientific Sessions 2019.
11. **Kohli P.** The “Sweet Spot”: Cardiovascular Risk Reduction in Diabetes. *Cardiology*, June 21, 2019. Coverage from ACC Scientific Sessions 2019. <https://www.acc.org/latest-in-cardiology/articles/2019/06/02/12/42/cover-story-the-sweet-spot-cardiovascular-risk-reduction-in-diabetes#.XRrj2PQsJR8.twitter>

#### **Professional educational materials or reports, online in print or other media**

1. **Kohli P** and Cannon CP. “Sugary Drinks and Coronary Heart Disease: What Does This Link Mean for Patient Care and Counseling?” March 2012. <http://www.consultantlive.com/cardiovascular->

- [diseases/content/article/10162/2049122](http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2049122).
2. **Kohli P** and Cannon CP. “Eating Red Meat Now Associated with Cardiovascular and Cancer Mortality”, March 2012. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2056236>.
  3. **Kohli P** and Cannon CP. “Novel LDL Lowering Agents: An Overview of PCSK9 as a Drug Target for Cholesterol Lowering” March 2012. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2054669?cid=intraarticle#>.
  4. **Kohli P**. “Statins in Primary Prevention: An Interview with Dr. Rita Redberg.” March 2012. <http://www.cardiosource.org>.
  5. **Kohli P** and Cannon CP. “Did Heart Disease Kill Whitney Houston?” April 2012. <http://www.consultantlive.com/display/article/10162/2060676>.
  6. **Kohli P** and Cannon CP. “More Frequent Chocolate Consumption Linked to Lower BMI” April 2012. <http://www.consultantlive.com/multimedia/content/article/10162/2065637>
  7. **Kohli P**, Bhatt DL and Cannon CP. “Bariatric Surgery Bests Medical Therapy Alone in Obese Patients with Diabetes” April 2012. <http://www.consultantlive.com/diabetestype2/content/article/10162/2058428>.
  8. **Kohli P** and Cannon CP. “The New Oral Anti-Coagulants: Benefits, Risks and Patient Selection” May 2012. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2074901>
  9. **Kohli P** and Cannon CP. “HDL Cholesterol: Why Higher Levels No Longer Equal Lower Risk” June 2012. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2085045?CID=rss>.
  10. **Kohli P** and Cannon CP. “Antiplatelet Therapy With Aspirin: What Dose in Primary and Secondary Prevention?” June 2012. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2083637>.
  11. **Kohli P** and Cannon CP. “Frequent Coffee Consumption Linked to Longevity: Caffeine Buzz” <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2080960>
  12. **Kohli P** and Cannon CP. “Azithromycin Increases the Risk of Cardiovascular Death” June 2012. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2086119?CID=rss>.
  13. **Kohli P** and Cannon CP. “Statins Linked to Exertional Fatigue” June 2012. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2086608>.
  14. **Kohli P** and Cannon CP. “Peri-procedural Anticoagulation: Novel Agents, New Rules” July 2012. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2088141>.
  15. **Kohli P** and Cannon CP. “Systemic Inflammation and Use of Diet to Stem Disease” July 2012. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2094112>.
  16. **Kohli P** and Bhatt DL. “Omega-3 Fatty Acid Therapy: What Comes Next?” August 2012. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2098081>.
  17. **Kohli P** and Blumenthal R. “Cardiovascular Prevention Revisited.” August 2012. <http://www.consultantlive.com>
  18. **Kohli P** and Yeghiazarians Y. “Myocardial Infarction: New Meaning Same Name” September 2012. <http://www.consultantlive.com/display/article/10162/2107934>.
  19. **Kohli P** and Bangalore S. “Who Needs Beta Blockers? Analysis Raises Questions” October 2012. <http://www.consultantlive.com/cardiology-now/content/article/10162/2110382>.
  20. **Kohli P** and Giugliano RP. “PCSK9 inhibition: An Update and Future Horizons” November 2012. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2116748>.
  21. **Kohli P** and Fang J. “Uncertain Thienopyridine Bioavailability After Bare-Metal Stent Placement.” <http://www.cardioexchange.org/discussion/uncertain-thienopyridine-bioavailability-after-bare-metal-stent-placement/>. Posted Jan 14, 2013.
  22. **Kohli P** and McGuire D. “Overview of DPP-4 inhibitors.” January 2013. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2129971>.
  23. **Kohli P**. “Yoga Calms More Than Just the Mind.” February 2013 <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2127980>.
  24. **Kohli P**. “Beta-Blockers in Heart Failure Patients with Atrial Fibrillation: Do They Really Save Lives?” March 2013 <http://www.consultantlive.com/atrial-fibrillation/content/article/10162/2132718>.
  25. **Kohli P** and Blaha M. “The Mediterranean Diet in Primary Cardiovascular Prevention.” March 2013. <http://www.consultantlive.com/cardiology-now/content/article/10162/2133620>
  26. **Kohli P** and Bairey Merz C. “Women and Heart Disease: Incidence, Prevalence, Progress, and The Future.” April 2013. <http://www.consultantlive.com/cardiology-now/content/article/10162/2136158>.

27. **Kohli P.** When Anticoagulation Isn't an Option: What To Do? April 2013.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2136501>.
28. **Kohli P.** “Interruption of Rivaroxaban vs. Warfarin for AF: A Comparison of Risk.” April 2013.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2136495>.
29. **Kohli P.** When the CHADS2 Score=1: Will Aspirin Do or Is Warfarin Indicated? May 2013.  
<http://www.consultantlive.com/atrial-fibrillation/content/article/10162/2142685>.
30. **Kohli P.** Eplerenone Reduces Atrial Fibrillation Incidence in Heart Failure Patients. May 2013.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2142649>.
31. **Kohli P.** Periprocedural Dabigatran: Risk for Increased Bleeding, Thromboembolism. June 2013.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2146256>
32. **Kohli P.** Bleeding Risk in AF: Tools for Clinical Assessment. June 2013.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2146404>.
33. **Kohli P.** Atherosclerosis: TMAO and Evidence for the “Infectious” Hypothesis.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2147787>. June 2013.
34. **Kohli P.** Apixaban: Effective in Acute VTE; Lower Risk of Major Bleeding.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2150824>. July 2013.
35. **Kohli P.** PTSD and Heart Disease: New Data Help Clarify the Connection.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2151544>. July 2013.
36. **Kohli P.** Low-Risk Lifestyle Protects Against Coronary Events, All-Cause Mortality.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2150862>. July 2013.
37. **Kohli P.** Oral Anticoagulation and Concomitant Use of Aspirin: Analysis of the ORBIT-AF Registry.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2153925>. August 2013.
38. **Kohli P.** President Bush’s Stress Test—and Stent: Guideline-Directed Care?  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2153947>. August 2013.
39. **Kohli P.** Artificial Sweeteners--Are They Better Than Sugar? <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2154010>. August 2013.
40. **Kohli P.** Novel Oral Anticoagulants and Food Intake: Does It Matter?  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2154614>. August 2013.
41. **Kohli P.** Atrial Fibrillation: Patient Visit Checklist. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2155064>. August 2013.
42. **Kohli P.** Dabigatran May Pose Excess Risk in Patients With Mechanical Valves.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2157516>. September 2013.
43. **Kohli P.** Influenza and Ischemic Heart Disease: Does Vaccination for One Help Prevent the Other?  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2157531>. September 2013.
44. **Kohli P.** Is Screening for Asymptomatic Atrial Fibrillation Indicated?  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2157813>. September 2013.
45. **Kohli P.** Statins Beneficial for Primary Prevention in the Elderly. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2157536>. September 2013.
46. **Kohli P.** Ablation Therapy for Atrial Fibrillation: A Role for MRI in Predicting Success?  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2157661>. September 2013.
47. **Kohli P** and Mikus C. Statins Plus Exercise: New Study Questions the Combination.  
<http://www.consultantlive.com/cardiology-now/content/article/10162/2146579>. June 2013.
48. **Kohli P.** Novel Anticoagulants: Evidence-Based Patient Selection. July 2013.  
<http://www.consultantlive.com/display/article/10162/2149371?pageNumber=1>
49. **Kohli P.** From Rivaroxaban to Warfarin: How to Switch Safely. July 2013.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2149675>.
50. **Kohli P.** Novel Anticoagulants: Dosing Errors and Solutions. July 2013.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2149680>.
51. **Kohli P.** Can Prescribing a Cigarette Help Smokers Quit? October 2013.  
<http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2160848>.
52. **Kohli P.** The VitDISH Study: Vit D Supplementation Does Not Improve Isolated Systolic Hypertension in Older Patients. October 2013. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2160853>

53. **Kohli P.** Warfarin, Aspirin, Both, or Neither: What Would You Prescribe? October 2013. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2161498>.
54. **Kohli P.** Paroxysmal Atrial Fibrillation: How to Safely Restore Sinus Rhythm? October 2013. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2161385>.
55. **Kohli P.** In Patients With a Mechanical Valve, Which Agent for Oral Anticoagulation? October 2013. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2161380>.
56. **Kohli P.** Patterns in Aspirin Dosing and Interaction With Potent Thienopyridines Following Acute Coronary Syndromes. October 2013. <http://blog.cardiosource.org/post/patterns-in-aspirin-dosing-and-interaction-with-potent-thienopyridines-following-acute-coronary-syndromes/>
57. **Kohli P.** Does Rivaroxaban in Patients with AF Differ in Those with Prior MI? November 2013. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2162224>.
58. **Kohli P.** Beware Before Prescribing: Direct Thrombin Inhibitors Pose Increased Risk of MI. November 2013. <http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2162233>.
59. **Kohli P.** ACC/AHA Prevention Guidelines: Highlights of the Top 3 Changes. November 2013. <http://www.consultantlive.com/cardiovascular-diseases/accaha-prevention-guidelines-highlights-top-3-changes>.  
<http://www.consultantlive.com/cardiovascular-diseases/accaha-prevention-guidelines-highlights-top-3-changes>.
60. **Kohli P.** Regular Nut Consumption Linked with Lower Mortality. December 2013. <http://www.consultantlive.com/cardiovascular-diseases/regular-nut-consumption-linked-lower-mortality>.
61. **Kohli P.** Organic Milk: A Heart-Healthy Recipe? January 2014. <http://www.consultantlive.com/cardiovascular-diseases/organic-milk-heart-healthy-recipe>.
62. **Kohli P.** Caffeine and Atrial Fibrillation: Is There a Protective Effect? January 2014. <http://www.consultantlive.com/atrial-fibrillation/caffeine-and-atrial-fibrillation-there-protective-effect>.
63. **Kohli P.** Atrial Fibrillation: Bad for the Heart and the Soul. January 2014. <http://www.consultantlive.com/cardiovascular-diseases/atrial-fibrillation-bad-heart-and-soul>.
64. **Kohli P.** Dietary Fiber Intake Shows Inverse, Dose-Dependent Risk Ratio with CHD, CVD. January 2014. <http://www.consultantlive.com/cardiovascular-diseases/dietary-fiber-intake-shows-inverse-dose-dependent-risk-ratio-chd-cvd>.
65. **Kohli P.** Green Tea May Affect Absorption of Beta-Blocker. January 2014. <http://www.consultantlive.com/cardiovascular-diseases/green-tea-may-affect-absorption-beta-blocker>.
66. **Kohli P.** In Dialysis Patients with Atrial Fibrillation, Anticoagulation Offers No Benefit. January 2014. <http://www.consultantlive.com/atrial-fibrillation/dialysis-patients-atrial-fibrillation-anticoagulation-offers-no-benefit>.
67. **Kohli P.** Diabetes Self-care App: The Next New Rx? February 2014. <http://www.consultantlive.com/diabetes-type-2/diabetes-self-care-app-next-new-rx>.
68. **Kohli P.** New OSA Treatment Uses Implanted Device. February 2014. <http://www.consultantlive.com/cardiovascular-diseases/new-osa-treatment-uses-implanted-device>.
69. **Kohli P.** Genotype-guided Warfarin Dosing: Does it Improve TTR? February 2014. <http://www.consultantlive.com/atrial-fibrillation/genotype-guided-warfarin-dosing-does-it-improve-ttr>.
70. **Kohli P.** Complex LAA Shape Predicts Thromboembolic Risk. February 2014. <http://www.consultantlive.com/atrial-fibrillation/complex-laa-shape-predicts-thromboembolic-risk>.
71. **Kohli P.** RE-LY AF Registry: Hypertension Most Common Risk Factor Worldwide. February 2014. <http://www.consultantlive.com/atrial-fibrillation/re-ly-af-registry-hypertension-most-common-risk-factor-worldwide>.
72. **Kohli P.** Intensive Cardiovascular Risk Reduction Can Positively Alter Gene Expression. March 2014. <http://www.consultantlive.com/cardiovascular-diseases/intensive-cardiovascular-risk-reduction-can-positively-alter-gene-expression>.
73. **Kohli P.** Road Rage-like Anger Linked to Increased Cardiovascular Risk. March 2014. <http://www.consultantlive.com/cardiovascular-diseases/road-rage-anger-linked-increased-cardiovascular-risk>.
74. **Kohli P.** Ablation vs. Medication: Which First for Atrial Fibrillation and for Who? April 2014. <http://www.consultantlive.com/atrial-fibrillation/ablation-vs-medication-which-first-atrial-fibrillation-and-who>.
75. **Kohli P.** NSAID Use Increases Risk of Atrial Arrhythmias. April 2014. <http://www.consultantlive.com/atrial->

- [fibrillation/nsaid-use-increases-risk-atrial-arrhythmias](#).
76. **Kohli P.** 2014 Atrial Fibrillation Management Guidelines Released. April 2014. <http://www.consultantlive.com/atrial-fibrillation/2014-atrial-fibrillation-management-guidelines-released>.
  77. **Kohli P.** ACE Inhibitors and ARBs not Equivalent In Diabetics. April 2014. <http://www.consultantlive.com/cardiovascular-diseases/ace-inhibitors-and-arbs-not-equivalent-diabetics>.
  78. **Kohli P.** Statins May Improve Erectile Dysfunction: A New Way to Encourage Compliance? April 2014. <http://www.consultantlive.com/cardiovascular-diseases/statins-may-improve-erectile-dysfunction-new-way-encourage-compliance>.
  79. **Kohli P.** Abdominal Aortic Aneurysm: Screen Older Male Smokers, Says USPSTF. May 2014. <http://www.consultantlive.com/cardiovascular-diseases/abdominal-aortic-aneurysm-screen-older-male-smokers-says-uspstf>.
  80. **Kohli P.** Apixaban Comparable to Warfarin After Cardioversion for Atrial Fibrillation. May 2014. <http://www.consultantlive.com/atrial-fibrillation/apixaban-comparable-warfarin-after-cardioversion-atrial-fibrillation>.
  81. **Kohli P.** Uninterrupted Warfarin During Atrial Fibrillation Ablation Decreases Stroke Risk. May 2014. <http://www.consultantlive.com/atrial-fibrillation/uninterrupted-warfarin-during-atrial-fibrillation-ablation-decreases-stroke-risk>.
  82. **Kohli P.** What Regimen to Minimize Thromboembolic Risk and Bleeding? May 2014. <http://www.consultantlive.com/atrial-fibrillation/what-regimen-minimize-thromboembolic-risk-and-bleeding>.
  83. **Kohli P.** Cryptogenic Stroke: Is Occult Arrhythmia A Factor? June 2014. <http://www.consultantlive.com/atrial-fibrillation/cryptogenic-stroke-occult-arrhythmia-factor>.
  84. **Kohli P.** Bisphosphonates Increase Risk of Incident AF. June 2014. <http://www.consultantlive.com/atrial-fibrillation/bisphosphonates-increase-risk-incident-af>.
  85. **Kohli P.** Cryptogenic Stroke: Is Occult Arrhythmia A Factor? June 2014. <http://www.consultantlive.com/atrial-fibrillation/cryptogenic-stroke-occult-arrhythmia-factor>.
  86. **Kohli P.** The Death of "Lone Atrial Fibrillation". June 2014. <http://www.consultantlive.com/atrial-fibrillation/death-lone-atrial-fibrillation>.
  87. **Kohli P.** Vegetarian Diet Reduces BP, Study Finds. June 2014. <http://www.consultantlive.com/cardiovascular-diseases/vegetarian-diet-reduces-bp-study-finds>.
  88. **Kohli P.** Which Change in Therapy Will Reduce CV Endpoints in T2DM? July 2014. <http://www.endocrinologynetwork.com/t2-diabetes/which-change-therapy-reduce-cv-endpoints-t2dm>.
  89. **Kohli P.** Ablation for Atrial Flutter: Treats the Arrhythmia but Not the Stroke Risk. July 2014. <http://www.consultantlive.com/atrial-fibrillation/ablation-atrial-flutter-treats-arrhythmia-not-stroke-risk>.
  90. **Kohli P.** Efficacy, Safety of Edoxaban by AF Subtype: An Analysis from ENGAGE AF-TIMI 48. **July 2014.** <http://www.consultantlive.com/atrial-fibrillation/efficacy-safety-edoxaban-af-subtype-analysis-engage-af-timi-48>.
  91. **Kohli P.** July 2014. Apixaban Most Cost-Effective of New Oral Anticoagulants. <http://www.consultantlive.com/atrial-fibrillation/apixaban-most-cost-effective-new-oral-anticoagulants>.
  92. **Kohli P.** August 2014. [Alcohol Intake and Atrial Fibrillation: Even Moderation is Risky.](http://www.consultantlive.com/atrial-fibrillation/alcohol-intake-and-atrial-fibrillation-even-moderation-risky) <http://www.consultantlive.com/atrial-fibrillation/alcohol-intake-and-atrial-fibrillation-even-moderation-risky>.
  93. **Kohli P.** August 2014. [Biomarkers May Enhance Risk Stratification in AF, Studies Show.](http://www.consultantlive.com/atrial-fibrillation/biomarkers-may-enhance-risk-stratification-af-studies-show) <http://www.consultantlive.com/atrial-fibrillation/biomarkers-may-enhance-risk-stratification-af-studies-show>.
  94. **Kohli P.** August 2014. Effective Screening Tool for AF: Patient Detection of Radial Arterial Pulse. <http://www.consultantlive.com/atrial-fibrillation/effective-screening-tool-af-patient-detection-radial-arterial-pulse>.
  95. **Kohli P.** September 2014. Statins and New-onset Diabetes: Who is at Risk? <http://www.endocrinologynetwork.com/cardiovascular-health/statins-and-new-onset-diabetes-who-risk>.
  96. **Kohli P.** September 2014. Perioperative AF: Not as Innocuous as It Seems. <http://www.consultantlive.com/atrial-fibrillation/perioperative-af-not-innocuous-it-seems>.
  97. **Kohli P.** September 2014. Beware Use of Foxglove in New-Onset Atrial Fibrillation. <http://www.consultantlive.com/atrial-fibrillation/beware-use-foxglove-new-onset-atrial-fibrillation>.
  98. **Kohli P.** September 2014. Exercise Lowers Risk of AF in Older, Obese Women. <http://www.consultantlive.com/atrial-fibrillation/exercise-lowers-risk-af-older-obese-women>.
  99. **Kohli P.** October 2014. iECG May Prove Cost-Effective for Screening Occult Atrial Fibrillation.

- <http://www.consultantlive.com/atrial-fibrillation/iecg-may-prove-cost-effective-screening-occult-atrial-fibrillation>.
100. **Kohli P.** October 2014. Cerebral Microbleeds in Atrial Fibrillation Portend Poor Prognosis. <http://www.consultantlive.com/atrial-fibrillation/cerebral-microbleeds-atrial-fibrillation-portend-poor-prognosis>.
101. **Kohli P.** October 2014. Community-Wide Screening for AF Reduces Stroke. <http://www.consultantlive.com/atrial-fibrillation/community-wide-screening-af-reduces-stroke>.
102. **Kohli P.** October 2014. Type 2 Diabetes Diagnosis: Which Test Would you Choose? <http://www.consultantlive.com/t2-diabetes/type-2-diabetes-diagnosis-which-test-would-you-choose>.
103. **Kohli P.** November 2014. Trends in Atrial Fibrillation Therapy: 2002-2011. <http://www.consultantlive.com/atrial-fibrillation/trends-atrial-fibrillation-therapy-2002-2011>.
104. **Kohli P.** November 2014. Atrial Fibrillation Characteristics Linked to Dementia. <http://www.consultantlive.com/atrial-fibrillation/atrial-fibrillation-characteristics-linked-dementia>.
105. **Kohli P.** November 2014. Fish Oils Fail to Impact Endpoints in AF. <http://www.consultantlive.com/atrial-fibrillation/fish-oils-fail-impact-endpoints-af>.
106. **Kohli P.** November 2014. Who Should Be Screened for Diabetes? <http://www.consultantlive.com/cardiovascular-health/who-should-we-screen-diabetes>.
107. **Kohli P.** December 2015. Dabigatran Increases “Real-World” Bleeding. <http://www.consultantlive.com/atrial-fibrillation/dabigatran-increases-“real-world”-bleeding>.
108. **Kohli P.** December 2015. Amiodarone-warfarin Interaction Ups Risk in ARISTOTLE Patients. <http://www.consultantlive.com/atrial-fibrillation/amiodarone-warfarin-interaction-ups-risk-aristotle-patients>.
109. **Kohli P.** February 2015. SGLT2 Inhibitor Q & A. <http://www.endocrinologynetwork.com/sglt2/sglt2-inhibitor-q>.
110. **Kohli P.** February 2015. Four Facts to Remember Before Prescribing a GLP-1 Agonist. <http://www.endocrinologynetwork.com/GLP-1/four-facts-remember-prescribing-glp-1-agonist>.
111. **Kohli P.** February 2015. Primary Care Quiz: CHA2DS2-VASc Stroke Risk Calculator. <http://www.consultantlive.com/atrial-fibrillation/primary-care-quiz-cha2ds2-vasc-stroke-risk-calculator>.
112. **Kohli P.** February 2015. Top 5 Things to Remember About Rhythm Control in AF. <http://www.consultantlive.com/atrial-fibrillation/top-5-things-remember-about-rhythm-control-af>.
113. **Kohli P.** February 2015. Game Change in the World of Atrial Fibrillation. <http://www.consultantlive.com/atrial-fibrillation/game-change-world-atrial-fibrillation>.
114. **Kohli P.** March 2015. Weight Loss Improves Atrial Fibrillation, Cardiometabolic Profile. <http://www.consultantlive.com/atrial-fibrillation/weight-loss-improves-atrial-fibrillation-cardiometabolic-profile>.
115. **Kohli P.** March 2015. Atrial Fibrillation: More Than An Electrical Problem. <http://www.consultantlive.com/atrial-fibrillation/atrial-fibrillation-more-electrical-problem>.
116. **Kohli P.** April 2015. To Ablate, or Not to Ablate? How Will You Answer the Question? <http://www.consultantlive.com/cardiovascular-diseases/ablate-or-not-ablate-how-will-you-answer-question-0>.
117. **Kohli P.** May 2015. Three Myths About New Oral Anticoagulants Debunked for Primary Care Physicians. <http://www.consultantlive.com/cardiovascular-diseases/3-myths-about-new-oral-anticoagulants-debunked-primary-care-physicians>.
118. **Kohli P.** May 2015. Just Say No to Anticoagulation for These Patients with Atrial Fibrillation. <http://www.consultantlive.com/cardiovascular-diseases/just-say-no-anticoagulation-these-patients-atrial-fibrillation>.
119. **Kohli P.** May 2015. Gender Affects Exercise Tolerance in Atrial Fibrillation. <http://www.consultantlive.com/cardiovascular-diseases/gender-affects-exercise-tolerance-atrial-fibrillation>.
120. **Kohli P.** May 2015. Another Win for Uninterrupted Anticoagulation in the OR. <http://www.consultantlive.com/cardiovascular-diseases/another-win-uninterrupted-anticoagulation-or>.
121. **Kohli P.** May 2015. SGLT2 Inhibitors: Check Your A1c and BPs. <http://www.consultantlive.com/diabetes/sglt2-inhibitors-check-your-a1c-and-bps>.
122. **Kohli P.** May 2015. GLP-1: Used Only As Needed. <http://www.consultantlive.com/diabetes/glp-1-used-only-needed>.
123. **Kohli P.** May 2015. Dapagliflozin Plus Exenatide: Better Weight Loss Together? <http://www.consultantlive.com/diabetes/dapagliflozin-plus-exenatide-better-weight-loss-together>.
124. **Kohli P.** July 2015. Three Things You (Still) Need to Know About GLP-1 Agonists.

- <http://www.consultantlive.com/diabetes/3-things-you-still-need-know-about-glp-1-agonists>.
125. **Kohli P.** July 2015. GLP-1 Agonist Pop Quiz. <http://www.consultantlive.com/quiz/glp-1-agonist-pop-quiz>.
  126. **Kohli P.** July 2015. Indications and Mechanism of SGLT2 Inhibitors in Type 2 Diabetes. <http://www.consultantlive.com/diabetes/indications-and-mechanism-sgl2-inhibitors-type-2-diabetes>.
  127. **Kohli P.** August 2015. Progression of Atrial Fibrillation: 3 Questions. <http://www.consultantlive.com/atrial-fibrillation/progression-atrial-fibrillation-3-questions>
  128. **Kohli P.** August 2015. 3D Printing Technology in Cardiac Procedure Planning. <http://www.consultantlive.com/atrial-fibrillation/3d-printing-technology-cardiac-procedure-planning>.
  129. **Kohli P.** September 2015. Persistent AF improved via LAA isolation. <http://www.consultantlive.com/atrial-fibrillation/persistent-af-improved-laa-isolation>.
  130. **Kohli P.** September 2015. ESC '15: Real World Patients, Real World Numbers from GARFIELD-AF. <http://www.consultantlive.com/atrial-fibrillation/esc-15-real-world-patients-real-world-numbers-garfield-af>.
  131. **Kohli P.** September 2015. An SGLT2 Inhibitor in the Works. <http://www.consultantlive.com/sglt2/sglt2-inhibitor-works>.
  132. **Kohli P.** July 2016. Anticoagulation for Atrial Fibrillation: Brief 3 Q and A. <http://www.consultantlive.com/atrial-fibrillation/anticoagulation-atrial-fibrillation-brief-3-q-and>.
  133. **Kohli P.** July 2016. Drivers with Atrial Fibrillation Proceed with Caution. <http://www.consultantlive.com/atrial-fibrillation/drivers-atrial-fibrillation-proceed-caution>.
  134. **Kohli P.** April 2017. Refining Terms in AF: Moving Away from “Valvular” and “Nonvalvular”. <http://www.patientcareonline.com/atrial-fibrillation/refining-terms-afib-moving-away-valvular-and-nonvalvular>
  135. **Kohli P.** May 2017. New-onset Afib in a Patient with CKD: A Case-based Quiz. <http://www.patientcareonline.com/atrial-fibrillation/food-and-atrial-fibrillation-good-eats-and-bad>.
  136. **Kohli P.** May 2017. Beware Digoxin for Atrial Fibrillation. <http://www.patientcareonline.com/atrial-fibrillation/beware-digoxin-atrial-fibrillation>.
  137. **Kohli P.** June 2017. Food and Atrial Fibrillation. <http://www.patientcareonline.com/atrial-fibrillation/food-and-atrial-fibrillation-good-eats-and-bad>.
  138. **Kohli P.** September 2017. Should We Refer Symptomatic Patients for AF Ablation? <http://www.patientcareonline.com/atrial-fibrillation/should-we-refer-symptomatic-hf-patients-af-ablation>.
  139. **Kohli P.** September 2017. AF screening Leads the Charge in Cardiology’s Digital Revolution. <http://www.patientcareonline.com/atrial-fibrillation/af-screening-leads-charge-cardiologys-digital-revolution>.
  140. **Kohli P.** October 2017. Drug-Drug Interactions with DOACs: Proceed with Caution. <http://www.patientcareonline.com/atrial-fibrillation/drug-drug-interactions-doacs-proceed-caution>.
  141. **Kohli P.** October 2017. Atrial Fibrillation and Type I Diabetes: What’s The Link? <http://www.patientcareonline.com/atrial-fibrillation/atrial-fibrillation-and-type-i-diabetes-whats-link>.
  142. **Kohli P.** November 2017. Secondary Afib. ICU Bed 10. Trigger? Rx? <http://www.patientcareonline.com/atrial-fibrillation/secondary-afib-icu-bed-10-trigger-rx/?GUID=4E5AB3F7-70AA-4FD5-BBE7-29BB89D4E684&rememberme=1&ts=13112017>.
  143. **Kohli P.** November 2017. TSH normal FT4 trending up. What Risk for AF? <http://www.patientcareonline.com/atrial-fibrillation/tsh-normal-ft4-trending-what-risk-afib/?GUID=4E5AB3F7-70AA-4FD5-BBE7-29BB89D4E684&rememberme=1&ts=13112017>.
  144. **Kohli P.** December 2017. The New Data on Dabigatran: Are We Reassured or Still Questioning? <http://www.patientcareonline.com/atrial-fibrillation/new-data-dabigatran-are-we-reassured-or-still-questioning>.
  145. **Kohli P.** December 2017. Oral Anticoagulant Therapy and Renal Dysfunction: A Two Way Street? <http://www.patientcareonline.com/atrial-fibrillation/oral-anticoagulant-therapy-and-renal-dysfunction-two-way-street>.
  146. **Kohli P.** January 2018. Top 6 Afib Studies in 2017: Part I. <http://www.patientcareonline.com/atrial-fibrillation/top-6-afib-studies-2017-part-i>.
  147. **Kohli P.** January 2018. Top 6 Afib Studies in 2017: Part II. <http://www.patientcareonline.com/atrial-fibrillation/top-6-afib-studies-2017-part-ii>.
  148. **Kohli P.** February 2018. 5 Key Biomarkers in CVD Prevention. <http://www.patientcareonline.com/cardiovascular-diseases/5-key-biomarkers-cvd-prevention>.
  149. **Kohli P.** February 2018. Prophylactic LAA Closure for Stroke Prevention in AF: Is it Really As Good An Ideas

- As We Thought? <http://www.patientcareonline.com/atrial-fibrillation/prophylactic-laa-closure-stroke-prevention-af-it-really-good-idea-we-thought>.
150. **Kohli P.** February 2018. The Neurohormonal Axis of the Left Atrial Appendage. <http://www.patientcareonline.com/atrial-fibrillation/neurohormonal-axis-left-atrial-appendage>.
  151. **Kohli P.** March 2018. Anticoagulation Challenge II: The Older Patient. <http://www.patientcareonline.com/atrial-fibrillation/anticoagulation-challenge-ii-older-patient>.
  152. **Kohli P.** March 2018. Anticoagulation Challenge: The Post PCI Patient. <http://www.patientcareonline.com/atrial-fibrillation/anticoagulation-challenge-post-pci-patient>.
  153. **Kohli P.** April 2018. Post-CABG AF: Not So Benign. <http://www.patientcareonline.com/atrial-fibrillation/post-cabg-af-not-so-benign>.
  154. **Kohli P.** April 2018. Stroke Prevention in AF: What you're your Options? <http://www.patientcareonline.com/atrial-fibrillation/stroke-prevention-af-what-are-your-options>
  155. **Kohli P.** May 2018. Antidote for Factor Xa Inhibitors: Approved. <http://www.patientcareonline.com/atrial-fibrillation/antidote-factor-xa-inhibitors-approved>.
  156. **Kohli P.** May 2018. Nuts vs. Atrial Fibrillation. <http://www.patientcareonline.com/atrial-fibrillation/nuts-vs-atrial-fibrillation>
  157. **Kohli P.** June 2018. The CABANA Trial in AF: A Quiz and a Practice Question. <http://www.patientcareonline.com/atrial-fibrillation/cabana-trial-af-quiz-and-practice-question>.
  158. **Kohli P.** June 2018. Anticoagulation Brush-up: Q&A with Payal Kohli, MD. <http://www.patientcareonline.com/atrial-fibrillation/anticoagulation-brush-qa-payal-kohli-md>.
  159. **Kohli P.** July 2018. Catheter Ablation Effective for Afib in Adults with Congenital Heart Disease. <http://www.patientcareonline.com/atrial-fibrillation/catheter-ablation-effective-afib-adults-congenital-heart-disease>.
  160. **Kohli P.** July 2018. Another Reason to Consider NOACs. <http://www.patientcareonline.com/atrial-fibrillation/another-reason-consider-noacs>.
  161. **Kohli P.** August 2018. Case in Point: Would you Anticoagulate this Patient? <http://www.patientcareonline.com/atrial-fibrillation/case-point-would-you-anticoagulate-patient>.
  162. **Kohli P.** August 2018. Afib and Aflutter: Should We Be “Lumpers” or “Splitters”? <http://www.patientcareonline.com/atrial-fibrillation/afib-and-aflutter-should-we-be-lumpers-or-splitters>.
  163. **Kohli P.** September 2018. ARRIVE, ASCEND and the Future of Aspirin. <http://www.patientcareonline.com/atrial-fibrillation/arrive-ascend-and-future-aspirin>.
  164. **Kohli P.** September 2018. Ablation Complications: Proceed with Caution. <http://www.patientcareonline.com/atrial-fibrillation/ablation-complications-proceed-caution>.
  165. **Kohli P.** October 2018. New Afib Scoring System: Is it New or Just Different? <http://www.patientcareonline.com/atrial-fibrillation/new-afib-scoring-system-it-new-or-just-different>.
  166. **Kohli P.** October 2018. Stroke Rate Variability in Afib: Much Higher Than We Thought. <http://www.patientcareonline.com/atrial-fibrillation/stroke-rate-variability-afib-much-higher-we-thought>.
  167. **Kohli P.** November 2018. Opioid Epidemic and AF. <http://www.patientcareonline.com/atrial-fibrillation/opioid-epidemic-and-af>.
  168. **Kohli P.** November 2018. Athletes and AF: No Longer Synonymous. <http://www.patientcareonline.com/atrial-fibrillation/athletes-and-atrial-fibrillation-no-longer-synonymous>.
  169. **Kohli P.** December 2018. Top 3 Atrial Fibrillation Studies in 2018. <http://www.patientcareonline.com/atrial-fibrillation/top-3-atrial-fibrillation-studies-2018>.
  170. **Kohli P.** December 2018. EHR Alert Fatigue: An Anticoagulation Example. <http://www.patientcareonline.com/atrial-fibrillation/ehr-alert-fatigue-anticoagulation-example>.